MedTrace Logo

Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists

NCT04597983 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-10-23

No results posted yet for this study

Summary

This clinical study evaluates the effect of 500 mg of 2S-hesperidin for 8 weeks on performance (power generated in different metabolic zones), body composition (fat and muscle mass) and biochemical (antioxidant, inflammatory status) and metabolic (capillary blood in finger) markers in amateur cyclists. Our hypothesis is that chronic intake of 2S-hesperidin can improve performance (maximum power generated). To justify this hypothesis, we measured the parameters mentioned above, which could establish a cause-effect relationship between 2S-hesperidin intake and possible yield improvement.

Conditions

  • Power
  • Metabolic Disturbance
  • Change, Body Weight
  • Changes Fatty
  • Muscle Loss
  • Oxidative Stress
  • Inflammatory Response
  • Oxygen Deficiency
  • Acid-Base Imbalance
  • Electrolyte Disturbance

Interventions

DIETARY_SUPPLEMENT

2S-hesperidin

Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)

DIETARY_SUPPLEMENT

Placebo

Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.

Sponsors & Collaborators

  • Francisco Javier Martínez Noguera

    lead OTHER

Principal Investigators

  • Pedro Emilio Alcaraz Ramón · Catholic University of Murcia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-22
Primary Completion
2018-12-21
Completion
2018-12-21

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04597983 on ClinicalTrials.gov